Should valproate be taken during pregnancy?
The Australian Registry of Antiepileptic Drug Use in Pregnancy includes 172 instances in which women took sodium valproate, with or without other antiepileptic drugs, during pregnancy. These pregnancies resulted in a substantially higher (p < 0.05) rate of malformed offspring (15.1%) compared wit...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2005
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661607/ |
| id |
pubmed-1661607 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-16616072008-03-21 Should valproate be taken during pregnancy? Eadie, Mervyn J Vajda, Frank JE Original Research The Australian Registry of Antiepileptic Drug Use in Pregnancy includes 172 instances in which women took sodium valproate, with or without other antiepileptic drugs, during pregnancy. These pregnancies resulted in a substantially higher (p < 0.05) rate of malformed offspring (15.1%) compared with 348 pregnant women who took antiepileptic drugs other than valproate (2.3%) and 40 pregnancies in epileptic women who took no antiepileptic drugs (2.5%). At valproate doses of 1400 mg and below per day, the mean rate of pregnancies with fetal malformations was 6.42% and did not seem to be dose-dependent. At higher valproate doses, the mean rate of pregnancy with fetal malformation was 33.9% and appeared to increase with increasing drug dosage. This finding suggests the need for reappraisal of the use of valproate in women who may become pregnant or are pregnant whilst the drug is taken. The therapeutic policy adopted may depend on whether valproate doses below 1400 mg per day are regarded as safe for the fetus. This study indicates that the risk of malformation associated with such doses was just statistically significantly (p < 0.05) higher than that associated with other antiepileptic drugs. Various possible clinical scenarios are discussed. Dove Medical Press 2005-03 2005-03 /pmc/articles/PMC1661607/ /pubmed/18360539 Text en © 2005 Dove Medical Press Limited. All rights reserved |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Eadie, Mervyn J Vajda, Frank JE |
| spellingShingle |
Eadie, Mervyn J Vajda, Frank JE Should valproate be taken during pregnancy? |
| author_facet |
Eadie, Mervyn J Vajda, Frank JE |
| author_sort |
Eadie, Mervyn J |
| title |
Should valproate be taken during pregnancy? |
| title_short |
Should valproate be taken during pregnancy? |
| title_full |
Should valproate be taken during pregnancy? |
| title_fullStr |
Should valproate be taken during pregnancy? |
| title_full_unstemmed |
Should valproate be taken during pregnancy? |
| title_sort |
should valproate be taken during pregnancy? |
| description |
The Australian Registry of Antiepileptic Drug Use in Pregnancy includes 172 instances in which women took sodium valproate, with or without other antiepileptic drugs, during pregnancy. These pregnancies resulted in a substantially higher (p < 0.05) rate of malformed offspring (15.1%) compared with 348 pregnant women who took antiepileptic drugs other than valproate (2.3%) and 40 pregnancies in epileptic women who took no antiepileptic drugs (2.5%). At valproate doses of 1400 mg and below per day, the mean rate of pregnancies with fetal malformations was 6.42% and did not seem to be dose-dependent. At higher valproate doses, the mean rate of pregnancy with fetal malformation was 33.9% and appeared to increase with increasing drug dosage. This finding suggests the need for reappraisal of the use of valproate in women who may become pregnant or are pregnant whilst the drug is taken. The therapeutic policy adopted may depend on whether valproate doses below 1400 mg per day are regarded as safe for the fetus. This study indicates that the risk of malformation associated with such doses was just statistically significantly (p < 0.05) higher than that associated with other antiepileptic drugs. Various possible clinical scenarios are discussed. |
| publisher |
Dove Medical Press |
| publishDate |
2005 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661607/ |
| _version_ |
1611391500928679936 |